A recent report from Thomas Jefferson University discusses the developments in using antibodies for cancer therapeutics. The researchers highlight the factors that contribute to the success of these biological molecules, such as their origin, isotype, affinity, avidity, and mechanism of action. While antibodies have been successful in minimizing side effects compared to small molecules or systemic chemotherapy, therapeutic resistance is a concern. The researchers suggest that combination therapy may be the best approach for patient care. The report provides an overview of antibodies in cancer therapy, their efficacy, mechanism of resistance, and examples of FDA-approved molecules. [Extracted from the article]